DWC202518 not checked
Daewoong Pharmaceutical Co. LTD.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- T2DM (Type 2 Diabetes Mellitus)
- Main trialPhase 3
- “This study aims to evaluate the efficacy and safety of initial combination therapy with DWP16001 and DWC202518 compared to DWP16001 monotherapy and DWC202518 monotherapy in patients with Type 2 Diabetes Mellitus”In the company’s words, NCT07619833 on ClinicalTrials.gov
Other drugs for T2DM (Type 2 Diabetes Mellitus)
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- QLG1091Qilu Pharmaceutical · Phase 3
- SHR-3167Hengrui · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- LenbelintideAstraZeneca · Phase 3
Coming up1
- Nov 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Nov 2027 | To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026